Table 2.

Registrational Trials in Gene-Specific Inhibitors for Advanced Thyroid Cancers

Drug	Target(s)	Trial	Patient population	Trial design	Primary outcome
RAIR-DTC
Larotrectinib	TRK A, B, C	SCOUT and NAVIGATE (30)	19 Patients with NTRK fusion-positive RECIST measurable diseasea	Pooled results from three phase I/II trials	ORR = 79%
Entrectinib	TRK A, B, C, ROS1, ALK	ALKA, STARTRK 1&2 (31)	5 Patients with NTRK fusion-positive RECIST measurable disease	Pooled results from three phase I/II trials	ORR = 20%
Selpercatinib	RET	LIBRETTO-001 (36)	19 Patients with RET fusion-positive RECIST measurable diseaseb	Phase I/II	ORR = 79%
Pralsetinib	RET	ARROWc (37)
MTC
Selpercatinib	RET	LIBRETTO-001 (36)	55 Patients with prior vandetanib and/or cabozantinib and 88 patients with no prior vandetanib or cabozantinib, RECIST measurable	Phase I/II	ORR = 69% (prior vandetanib and/or cabozantinib); ORR = 73% (no prior vandetanib or cabozantinib)
Pralsetinib	RET	ARROWc (37)

^a Included seven patients with ATC.

^b Included two patients with ATC.

^c Results not published by the time of this writing.

ATC, anaplastic thyroid carcinoma; NTRK, neurotrophic tyrosine kinase receptor; ORR, objective response rate; RET, REarranged in Transfection.